Phase-change contrast agents for imaging and therapy.
Phase-change contrast agents for imaging and therapy.
复制标题
DOI：
10.2174/138161212800099883
复制
发表时间：
2012
影响因子：
3.1
通讯作者：
Dayton PA
中科院分区：
文献类型：
--
作者：
Sheeran PS;Dayton PA
用于基于超声的应用的相变造影剂（PCCA）已经导致了接近诊断和治疗技术的新方法，超出了微泡造影剂和液体乳剂的可能性。当经受由超声换能器递送的足够压力时，稳定的液滴经历到气态的相变并且发生体积膨胀。这种现象，称为声学液滴蒸发，已被提出作为一种手段，以解决在微米级和纳米级的体内应用的数量。在这篇综述中，PCCAs的历史，所涉及的物理机制，并提出了应用程序进行了讨论，在体内的研究表明，总结。影响PCCA设计的因素进行了讨论，以及需要为未来的研究，以表征潜在的生物效应，在人类管理和优化超声参数。
Phase-change contrast agents (PCCAs) for ultrasound-based applications have resulted in novel ways of approaching diagnostic and therapeutic techniques beyond what is possible with microbubble contrast agents and liquid emulsions. When subjected to sufficient pressures delivered by an ultrasound transducer, stabilized droplets undergo a phase-transition to the gaseous state and a volumetric expansion occurs. This phenomenon, termed acoustic droplet vaporization, has been proposed as a means to address a number of in vivo applications at the microscale and nanoscale. In this review, the history of PCCAs, physical mechanisms involved, and proposed applications are discussed with a summary of studies demonstrated in vivo. Factors that influence the design of PCCAs are discussed, as well as the need for future studies to characterize potential bioeffects for administration in humans and optimization of ultrasound parameters.